Literature DB >> 2209699

Interleukin 6 is a differentiation factor for human megakaryocytes in vitro.

H Kimura1, T Ishibashi, T Uchida, Y Maruyama, P Friese, S A Burstein.   

Abstract

The response of cells of the megakaryocytic lineage to interleukin 6 (IL6), a cytokine with multiple biological activities, was studied by adding the factor to human bone marrow (BM) cultures. IL6 alone had no effect on megakaryocytic colony formation in methylcellulose; however, in the presence of maximally stimulating concentrations of IL 3, almost a twofold increment in colony formation was observed. Tritiated thymidine suicide studies of BM incubated for 2 h with growth factors showed that almost one-half of megakaryocytic progenitors (CFU-Mk) preincubated with IL3 or IL3 plus IL6 were in S phase, whereas BM incubated with IL6 alone was similar to control (approximately 24% of CFU-Mk in S phase). When greater than or equal to 1 ng/ml of IL6 was added to liquid suspension cultures of BM, the size of individual megakaryocytes was significantly augmented compared with that seen in control cultures. Moreover, the DNA content of megakaryocytes grown in the presence of IL6 was increased (modal ploidy 16N) compared with cultures grown with IL3 (modal ploidy 8N). To determine if the effect of IL6 could be direct rather than mediated via accessory BM cells, the factor was added to cultures of isolated single megakaryocytes. Seventy-one percent of cells increased in diameter in the presence of IL6, while only 27% increased in size in the absence of the factor. The data show that IL6 is a direct maturation factor for human megakaryocytes, promoting increments in size and ploidy of these cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2209699     DOI: 10.1002/eji.1830200909

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Potential role of interleukin 6 in reactive thrombocytosis and acute phase response in pulmonary tuberculosis.

Authors:  E Unsal; S Aksaray; D Köksal; T Sipit
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

2.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

3.  Impaired T cell signal transduction through CD28 in a patient with idiopathic thrombocytopenia.

Authors:  M Pérez-Blas; A Arnaiz-Villena; R Góngora; O G Segurado; J L Vivanco; J R Regueiro
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

4.  Mitigation of Lethal Radiation Syndrome in Mice by Intramuscular Injection of 3D Cultured Adherent Human Placental Stromal Cells.

Authors:  Elena Gaberman; Lena Pinzur; Lilia Levdansky; Maria Tsirlin; Nir Netzer; Zami Aberman; Raphael Gorodetsky
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

5.  Roles of IL-6-gp130 Signaling in Vascular Inflammation.

Authors:  Tieying Hou; Brian C Tieu; Sutapa Ray; Adrian Recinos Iii; Ruwen Cui; Ronald G Tilton; Allan R Brasier
Journal:  Curr Cardiol Rev       Date:  2008-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.